Abstract

A REVIEW OF POTENTIAL TREATMENTS FOR NOVEL CORONA VIRUS DISEASE (COVID-19)

Ankit Kumar*, Qurratul Ain, Ritul Gupta, Anchal Rai, Ikram and Nishant Kumar Sharma

ABSTRACT

The severe acute respiratory syndrome corona virus-2 (SARS-CoV2) outbreak has turned into a global pandemic. Corona-virus disease 2019 (COVID-19) can cause a wide range of symptoms, from moderate illness to severe respiratory failure necessitating hospitalization. Critical care teams are faced with difficult treatment decisions as the incidence continues to climb at a rapid rate. In the pharmacologic management of COVID-19 patients, there is currently no universally established standard of care. A priority is to identify relevant treatment solutions as soon as possible. Novel agents, as well as existing medicines, repurposed antiviral, and immunomodulating therapy, are available in clinical studies or through compassionate use. Many have shown potential against other viruses that are related to SARS-CoV-2 in vitro or in vivo. Adjustments for organ impairment and renal replacement therapies, complex lists of concurrent medications, limitations with drug administration and compatibility, and unique toxicities that should be evaluated when using these therapies are all important considerations for critically ill patients with COVID-19.

Keywords: Covid-19, Hydroxycloroquine (HCQ), Remdesivir, Ritonavir, SARS-CoV-2.